
Zoetis Inc.
ZTSNYSEHealthcareDrug Manufacturers - Specialty & Generic
前收盘价
US$77.74
+US$2.72 · +3.63%
盘前
US$78.23
+US$0.49 · +0.63%
8月24日 4:52 ET
ZTS公司概览
盘中时间采用ET。市场数据可能有所延迟。
GoAI 研究快照
简明呈现最新可用的模型信息。
GoAI评分
Buy
Favorable setup — positive multi-factor alignment
估值
96
Deep Value
动量
25
Weakening
情绪
66
Bullish
风险韧性
57
Elevated Risk
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
人工智能生成的上下文仅供参考,并非投资建议。
公司概况
公司网站Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- 行业
- Drug Manufacturers - Specialty & Generic
- 部门
- Healthcare
- 总部
- US
- 首席执行官
- Kristin C. Peck
- 上市以来
- 2013年2月1日
- 雇员
- 14,500
市场位置
日内区间
当前US$77.74,
52周区间
当前US$77.74,
- 开盘价
- US$75.29
- 前收盘价
- US$75.02
- 成交量
- 439.22万
- 0.63× 平均值
- 平均成交量
- 698.57万
- 日均成交量
- 市值
- 325.91亿 USD
- 贝塔
- 0.73
- 市场参考 1
- 50天平均值
- US$76.0074
- 高于平均水平+2.28%
- 200天平均值
- US$105.57
- 低于平均水平-26.36%
财务数据
财务快照
最近十二个月估值与收益率
- 企业价值
- 629.75亿 USD
- EV/EBITDA
- 15.48×
- 盈利收益率
- 4.79%
- 自由现金流收益率
- 4.09%
盈利能力和效率
- 净资产收益率
- 80.25%
- 资产收益率
- 17.28%
- 投入资本回报率
- 21.54%
财务健康
- 流动比率
- 3.03×
- 奥特曼 Z 分数
- 4.74
- 皮奥特罗斯基 F 分数
- 7 共 9 个
财报历史与展望
- 最新财年每股收益
- 6.02
- 2025财年 · 同比+10.05%
- 最新财年收入
- 94.67亿 USD
- 2025财年 · 同比+2.28%
- 下一财年每股收益共识
- 6.29
- 2026财年 · 10位分析师
- 下一财年收入共识
- 93.15亿 USD
- 2026财年 · 11位分析师
年度每股收益趋势
已公布业绩及可用的市场共识预期。
年度营收趋势
已公布业绩及可用的市场共识预期。
ZTS同业公司
继续GoAI的研究
在 GoAI 中研究ZTSresearch.disclaimer





